Clay B. Siegall co-founded Seattle Genetics in 1998. It is based on scientific innovation, thorough research, drug creation practices and a passion for helping the patients. Through Dr. Siegall’s guidance, the company is the leading developer of antibody-drug conjugates (ADC’s) and secured the Food and Drug Approval in 2011 for ADCETRIS (brentuximab vedotin) which became a global brand in over 65 countries when Seattle Genetics partnered with Takeda Pharmaceutical Company. Seattle Genetics is also leading in the diverse pipeline for cancer therapies that are antibody-based.

Clay Siegall, the company’s chief executive officer, president and chairman of the board, has made Seattle Genetics enter various strategic licenses like AbbVie, Genentech and GlaxoSmithKline, and Pfizer that have generated over $350million, for its Antibody conjugates technology. In clinical development, over 20ADC’s, both internal and collaborator programs use Seattle Genetics technology. Dr. Siegall has also steered capital raising activities for the company raising more than $1.2 billion in public and private funding including the company’s IPO in 2011.

Dr. Siegall worked with the National Cancer Institute from 1988 to 1991. He then moved to Bristol-Myers Squibb Pharmaceutical research institute where he worked from 1991 to 1997. After that, he co-founded Seattle Genetics in 1998. He currently serves as one of the directors in various boards including Washington Roundtable, Alder BioPharmaceuticals, and Ultragenyx pharmaceuticals.

When asked in his interview by IdeaMensch where his idea for Seattle genetics came from, Dr. Clay Siegall says the five years cancer progression his father had, made him realize that oncologists have limited tools at the time and so he wanted to improve them. He had a genetics doctorate from George Washington University and worked at the pharmaceutical research institute for Bristol-Myers Squibb that brought him to Seattle Genetics with the best experience of running a company. His goal is to treat cancer patients and offer better than what the world currently has.

The one strategy that has helped Seattle genetics grow is the collaboration it has with other leaders in the industry and oncology drug development innovators. Dr. Siegall’s recommendation as an entrepreneur is that people should learn as much as they can and should interact with smart people with many areas of expertise.